|
| Wednesday, February 27, 2019 |
|
|
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan |
| Eisai Co., Ltd. has entered an agreement to support the international non-governmental organization Association for Aid and Relief, Japan's program to raise awareness of mycetoma in Sudan. more info >> |
|
| Thursday, February 21, 2019 |
|
|
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」について国内で初めて化膿性汗腺炎の適応追加承認を取得 |
| アッヴィ合同会社（本社：東京都、社長：ジェームス・フェリシアーノ、以下 アッヴィ）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」（一般名：アダリムマブ＜遺伝子組換え＞、以下「ヒュミラ」）について、化膿性汗腺炎（Hidradenitis Suppurativa：HS）の適応追加承認を本日取得したことをお知らせします。 more info >> |
|
|
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa |
| AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant]), a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa (HS). more info >> |
|
| Wednesday, February 13, 2019 |
|
|
エーザイ、抗てんかん剤「Fycompa(R)」について欧州において小児てんかんに係る適応で承認申請を提出 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、自社創製の抗てんかん剤「Fycompa(R)」（一般名：ペランパネル、日本製品名：「フィコンパ(R)」)について、欧州医薬品庁（EMA）に対して、小児てんかんに係る適応拡大の追加申請を行いましたのでお知らせします。 more info >> |
|
|
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy |
| Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency (EMA) for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy. more info >> |
|
|
エーザイ、人事異動ならびに組織改編（2019年2月12日付）を発表 |
| エーザイ株式会社は12日、人事異動ならびに組織改編（2019年2月12日付）を以下のとおり発表しました。 more info >> |
|
| Monday, February 4, 2019 |
|
|
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study |
| Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
| Monday, November 20, 2017 |
|
|
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December |
| Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Friday, November 17, 2017 |
|
|
エーザイ、ドイツにおいて公的医療保険中央連合会との合意に基づき、抗てんかん剤「Fycompa(R)」の販売を12月に再開 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、ドイツ医薬品販売会社である Eisai GmbH（所在地：フランクフルト）が、抗てんかん剤「Fycompa(R)」（一般名：ペランパネル、日本製品名「フィコンパ(R)」)について、公的医療保険中央連合会（GKV-Spitzenverband）と償還価格に関して合意し、2017年12月1日よりドイツでの「Fycompa」の販売を再開することをお知らせします。 more info >> |
|
| Monday, November 6, 2017 |
|
|
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen Inc. (Nasdaq: BIIB) presented new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, an investigational treatment for Alzheimer's disease at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting, Boston, Massachusetts, United States, from November 1 to 4. more info >> |
|
|
|
|
